Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
2001 1
2002 1
2003 4
2004 1
2005 1
2009 1
2010 1
2016 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

11 results
Results by year
Filters applied: . Clear all
Page 1
Seventeen-year follow-up of the prospective randomized Nordic CIS study: BCG monotherapy versus alternating therapy with mitomycin C and BCG in patients with carcinoma in situ of the urinary bladder.
Kaasinen E, Wijkström H, Rintala E, Mestad O, Jahnson S, Malmström PU. Kaasinen E, et al. Among authors: mestad o. Scand J Urol. 2016 Oct;50(5):360-8. doi: 10.1080/21681805.2016.1210672. Epub 2016 Aug 15. Scand J Urol. 2016. PMID: 27603424 Clinical Trial.
Bacillus Calmette-Guérin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study.
Duchek M, Johansson R, Jahnson S, Mestad O, Hellström P, Hellsten S, Malmström PU; Members of the Urothelial Cancer Group of the Nordic Association of Urology. Duchek M, et al. Among authors: mestad o. Eur Urol. 2010 Jan;57(1):25-31. doi: 10.1016/j.eururo.2009.09.038. Epub 2009 Oct 6. Eur Urol. 2010. PMID: 19819617 Clinical Trial.
11 results